Efluelda from Sanofi S.A. - high-dose flu shot under EU scrutiny

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-27, 03:15. Details in the imprint.

The Efluelda influenza vaccine from Sanofi S.A. sits in steel trays in hospital fridges, its small glass vials promising a stronger shield for people aged 65 and over. Nurses describe the injection as a thicker, more viscous shot that fills the syringe with a quiet weight before it goes into an older patient's arm.

What Efluelda is meant to do

Efluelda is a high-dose quadrivalent influenza vaccine specifically indicated for adults 65 years and older, aiming to compensate for the weaker immune response in this age group. The formulation contains four influenza strains in higher antigen amounts than standard-dose vaccines to trigger a more robust antibody response. In practice, clinicians like Dr. Marie Dubois at a Paris geriatric clinic use it for patients they consider most vulnerable, including those with chronic heart or lung disease.

Sanofi positions Efluelda as part of its broader portfolio of influenza vaccines for Europe, where seasonal flu campaigns are largely organized through national health systems. The product is typically administered before the winter season, with vaccination programs starting in early autumn to ensure older adults build immunity ahead of peak circulation. Compared with classic trivalent or standard-dose quadrivalent shots, Efluelda's selling point is the extra antigen load tailored to seniors.

The EU probe changes the tone

On 26 June 2026, the European Commission opened an antitrust investigation into whether Sanofi used a misleading communication campaign to promote Efluelda while disparaging a rival senior flu vaccine, Fluad, marketed by CSL Seqirus. According to the Commission, the suspected conduct mainly took place in France and Germany, two of the largest flu vaccine markets in the bloc. The authority said it was concerned that Sanofi's campaign may have breached EU competition rules by unfairly influencing purchasing decisions in favor of Efluelda. CNBC reports on the EU Commission statement

Bloomberg cites the Commission as suspecting that Sanofi "illegally disparaged" CSL Seqirus' Fluad to boost Efluelda sales, potentially affecting public procurement and prescriber preferences. The investigation does not question Efluelda's regulatory approval or clinical profile, but focuses on how the product was marketed compared with its competitor. For now, the Commission has not reached a conclusion, and Sanofi, led by CEO Paul Hudson, states that it is cooperating with the authority and maintains that its promotional activities complied with applicable rules. Bloomberg summarizes the Commission's concerns

How the vaccine is used

In daily practice, Efluelda is given as a single intramuscular injection, usually into the upper arm muscle, with vaccination teams moving from bed to bed in nursing homes. Many patients feel only a brief sting and a sense of pressure as the thicker liquid enters, followed by common local reactions such as soreness or mild redness. Healthcare workers value the once-per-season dosing and the ability to align administration with other routine visits.

National immunization programs in Europe decide whether and how to include high-dose vaccines like Efluelda in public campaigns, often prioritizing people over 65 or those with specific risk factors. Procurement decisions can hinge on cost, comparative effectiveness data and logistics, so any perception that one vaccine is inferior to another can influence tender outcomes. That is precisely why the Commission is now dissecting Sanofi's past communication.

Where Efluelda fits in Sanofi's portfolio

For Sanofi, Efluelda sits alongside well-known influenza brands such as Vaxigrip and Fluzone, forming a vaccines franchise that delivers recurring seasonal revenue. The company has long targeted the senior segment as a key market, arguing that improved protection in older adults can reduce hospitalizations and healthcare costs during severe flu seasons. Efluelda's focus on high antigen content reflects Sanofi's strategy to differentiate on immunogenicity rather than purely on price.

Investors following the vaccines business pay attention to regulatory developments, including the current EU antitrust investigation, because reputational issues can spill over into contract negotiations and margin expectations. Efluelda itself remains authorized and used, but the scrutiny around its promotion could prompt changes in how future campaigns are designed, with internal compliance teams at Sanofi likely tightening review processes.

Company context and shares

Sanofi S.A. is a Paris-based global pharmaceutical group with strong positions in vaccines, specialty care and general medicines, and the Efluelda franchise is one of several seasonal products feeding its vaccines revenue. Sanofi shares (ISIN FR0000120578) trade on Euronext Paris, where institutional investors monitor news such as the EU Commission investigation when assessing regulatory risk and sentiment around the company's vaccines portfolio.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.